Literature DB >> 22128174

Modulation of heme/substrate binding cleft of neuronal nitric-oxide synthase (nNOS) regulates binding of Hsp90 and Hsp70 proteins and nNOS ubiquitination.

Hwei-Ming Peng1, Yoshihiro Morishima, William B Pratt, Yoichi Osawa.   

Abstract

Like other nitric-oxide synthase (NOS) enzymes, neuronal NOS (nNOS) turnover and activity are regulated by the Hsp90/Hsp70-based chaperone machinery, which regulates signaling proteins by modulating ligand binding clefts (Pratt, W. B., Morishima, Y., and Osawa, Y. (2008) J. Biol. Chem. 283, 22885-22889). We have previously shown that nNOS turnover is due to Hsp70/CHIP-dependent ubiquitination and proteasomal degradation. In this work, we use an intracellular cross-linking approach to study both chaperone binding and nNOS ubiquitination in intact HEK293 cells. Treatment of cells with N(G)-nitro-L-arginine, a slowly reversible competitive inhibitor that stabilizes nNOS, decreases both nNOS ubiquitination and binding of Hsp90, Hsp70, and CHIP. Treatment with the calcium ionophore A23187, which increases Ca(2+)-calmodulin binding to nNOS, increases nNOS ubiquitination and binding of Hsp90, Hsp70, and CHIP in a manner that is specific for changes in the heme/substrate binding cleft. Both Hsp90 and Hsp70 are bound to the expressed nNOS oxygenase domain, which contains the heme/substrate binding cleft, but not to the reductase domain, and binding is increased to an expressed fragment containing both the oxygenase domain and the calmodulin binding site. Overexpression of Hsp70 promotes nNOS ubiquitination and decreases nNOS protein, and overexpression of Hsp90 inhibits nNOS ubiquitination and increases nNOS protein, showing the opposing effects of the two chaperones as they participate in nNOS quality control in the cell. These observations support the notion that changes in the state of the heme/substrate binding cleft affect chaperone binding and thus nNOS ubiquitination.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22128174      PMCID: PMC3256889          DOI: 10.1074/jbc.M111.323295

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release.

Authors:  Jason Fontana; David Fulton; Yan Chen; Todd A Fairchild; Timothy J McCabe; Naoya Fujita; Takashi Tsuruo; William C Sessa
Journal:  Circ Res       Date:  2002-05-03       Impact factor: 17.367

2.  Guanabenz-mediated inactivation and enhanced proteolytic degradation of neuronal nitric-oxide synthase.

Authors:  S Noguchi; S Jianmongkol; A T Bender; Y Kamada; D R Demady; Y Osawa
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

3.  Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy.

Authors:  Ami Citri; Iris Alroy; Sara Lavi; Chanan Rubin; Wanping Xu; Nicolas Grammatikakis; Cam Patterson; Len Neckers; David W Fry; Yosef Yarden
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

4.  Determination of the enhancing action of HSP90 on neuronal nitric oxide synthase by EPR spectroscopy.

Authors:  Y Song; J L Zweier; Y Xia
Journal:  Am J Physiol Cell Physiol       Date:  2001-12       Impact factor: 4.249

5.  Hsp90 interacts with inducible NO synthase client protein in its heme-free state and then drives heme insertion by an ATP-dependent process.

Authors:  Arnab Ghosh; Mamta Chawla-Sarkar; Dennis J Stuehr
Journal:  FASEB J       Date:  2011-02-25       Impact factor: 5.191

6.  Reconstitution of an endothelial nitric-oxide synthase (eNOS), hsp90, and caveolin-1 complex in vitro. Evidence that hsp90 facilitates calmodulin stimulated displacement of eNOS from caveolin-1.

Authors:  J P Gratton; J Fontana; D S O'Connor; G Garcia-Cardena; T J McCabe; W C Sessa
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

7.  Hsp90 ensures the transition from the early Ca2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells.

Authors:  A Brouet; P Sonveaux; C Dessy; J L Balligand; O Feron
Journal:  J Biol Chem       Date:  2001-06-25       Impact factor: 5.157

8.  hsp90 is required for heme binding and activation of apo-neuronal nitric-oxide synthase: geldanamycin-mediated oxidant generation is unrelated to any action of hsp90.

Authors:  Scott S Billecke; Andrew T Bender; Kimon C Kanelakis; Patrick J M Murphy; Ezra R Lowe; Yasuhiko Kamada; William B Pratt; Yoichi Osawa
Journal:  J Biol Chem       Date:  2002-03-28       Impact factor: 5.157

9.  Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.

Authors:  W Xu; E Mimnaugh; M F Rosser; C Nicchitta; M Marcu; Y Yarden; L Neckers
Journal:  J Biol Chem       Date:  2000-11-08       Impact factor: 5.157

10.  Heat-shock protein 90 augments neuronal nitric oxide synthase activity by enhancing Ca2+/calmodulin binding.

Authors:  Y Song; J L Zweier; Y Xia
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

View more
  21 in total

1.  Hsp70:CHIP Ubiquitinates Dysfunctional but Not Native Neuronal NO Synthase.

Authors:  Amanda K Davis; Natalie F McMyn; Miranda Lau; Yoshihiro Morishima; Yoichi Osawa
Journal:  Mol Pharmacol       Date:  2020-06-26       Impact factor: 4.436

Review 2.  Molecular mechanisms of neuronal nitric oxide synthase in cardiac function and pathophysiology.

Authors:  Yin Hua Zhang; Chun Zi Jin; Ji Hyun Jang; Yue Wang
Journal:  J Physiol       Date:  2014-04-22       Impact factor: 5.182

3.  Proteomic analysis of the NOS2 interactome in human airway epithelial cells.

Authors:  Matthew W Foster; J Will Thompson; Michael T Forrester; Yonggang Sha; Timothy J McMahon; Dawn E Bowles; M Arthur Moseley; Harvey E Marshall
Journal:  Nitric Oxide       Date:  2013-02-21       Impact factor: 4.427

Review 4.  Nitric oxide synthase enzymology in the 20 years after the Nobel Prize.

Authors:  Dennis J Stuehr; Mohammad Mahfuzul Haque
Journal:  Br J Pharmacol       Date:  2018-12-09       Impact factor: 8.739

Review 5.  Specificity in S-nitrosylation: a short-range mechanism for NO signaling?

Authors:  Antonio Martínez-Ruiz; Inês M Araújo; Alicia Izquierdo-Álvarez; Pablo Hernansanz-Agustín; Santiago Lamas; Juan M Serrador
Journal:  Antioxid Redox Signal       Date:  2013-01-04       Impact factor: 8.401

6.  Chaperone Activity and Dimerization Properties of Hsp90α and Hsp90β in Glucocorticoid Receptor Activation by the Multiprotein Hsp90/Hsp70-Dependent Chaperone Machinery.

Authors:  Yoshihiro Morishima; Ranjit K Mehta; Miyako Yoshimura; Miranda Lau; Daniel R Southworth; Theodore S Lawrence; William B Pratt; Mukesh K Nyati; Yoichi Osawa
Journal:  Mol Pharmacol       Date:  2018-06-25       Impact factor: 4.436

Review 7.  Post-translational regulation of neuronal nitric oxide synthase: implications for sympathoexcitatory states.

Authors:  Neeru M Sharma; Kaushik P Patel
Journal:  Expert Opin Ther Targets       Date:  2016-12-02       Impact factor: 6.902

8.  Heat Shock Protein 90 Associates with the Per-Arnt-Sim Domain of Heme-free Soluble Guanylate Cyclase: IMplications for Enzyme Maturation.

Authors:  Anindya Sarkar; Yue Dai; Mohammad Mahfuzul Haque; Franziska Seeger; Arnab Ghosh; Elsa D Garcin; William R Montfort; Stanley L Hazen; Saurav Misra; Dennis J Stuehr
Journal:  J Biol Chem       Date:  2015-07-01       Impact factor: 5.157

9.  Potential roles of neuronal nitric oxide synthase and the PTEN-induced kinase 1 (PINK1)/Parkin pathway for mitochondrial protein degradation in disuse-induced soleus muscle atrophy in adult rats.

Authors:  Munehiro Uda; Toshinori Yoshihara; Noriko Ichinoseki-Sekine; Takeshi Baba; Toshitada Yoshioka
Journal:  PLoS One       Date:  2020-12-09       Impact factor: 3.240

Review 10.  A model in which heat shock protein 90 targets protein-folding clefts: rationale for a new approach to neuroprotective treatment of protein folding diseases.

Authors:  William B Pratt; Yoshihiro Morishima; Jason E Gestwicki; Andrew P Lieberman; Yoichi Osawa
Journal:  Exp Biol Med (Maywood)       Date:  2014-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.